酒精性肝病患者酒精应用障碍管理

doi:10.3969/j.issn.1672-5069.2025.01.001

Abstract

Sun Furong, Wang Bingyuan. Management of patients with alcohol consumption disorder[J]. Journal of Practical Hepatology, 2025, 28(1): 1-4.

[1] Schomerus G, Leonhard A, Manthey J,et al. The stigma of alcohol-related liver disease and its impact on healthcare. J Hepatol, 2022,77(2):516-524.
[2] Banini BA, Sanyal AJ. Treatment of NASH: What helps beyond weight loss? Am J Gastroenterol, 2017,112(6):821-824.
[3] Zhang X, Zhang X, Liu M, et al. Global, regional, and national burden of cirrhosis and other chronic liver diseases due to alcohol use, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. BMC Gastroenterol, 2022,22(1):484.
[4] Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 annual data report: Liver. Am J Transplant, 2017,17(Suppl 1):174-251.
[5] Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-associated liver disease. Am J Gastroenterol, 2024, 119(1):30-54.
[6] Shah ND, Ventura-Cots M, Abraldes JG, et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol, 2019,17(11):2320-2329.
[7] Younossi ZM, Stepanova M, Ong J, et al. Global NASH Council. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol, 2019,17(8):1625-1633.
[8] Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol, 2024,29(1):101133.
[9] Loomba R, Yang HI, Su J, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol, 2013,177(4):333-342.
[10] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023,77(5):1797-1835.
[11] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023,77(5):1797-1835.
[12] Ndugga N, Lightbourne TG, Javaherian K, et al. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open, 2017,7(3):e013620.
[13] Shoreibah M, Anand BS, Singal AK. Alcoholic hepatitis and concomitant hepatitis C virus infection. World J Gastroenterol, 2014,20(34):11929-11934.
[14] Singal AK, Leggio L, DiMartini A. Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin. Liver Transpl, 2024,30(2):200-212.
[15] Monnig MA, Treloar Padovano H, Monti PM. Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities. Front Public Health, 2024,12:1322460.
[16] Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. Hepatology, 2017,66(5):1464-1473.
[17] Pearson MM, Kim NJ, Berry K, et al. Associations between alcohol use and liver-related outcomes in a large national cohort of patients with cirrhosis. Hepatol Commun, 2021,5(12):2080-2095.
[18] Mellinger JL, Scott Winder G, DeJonckheere M, et al. Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis. J Subst Abuse Treat, 2018,91:20-27.
[19] Haque LY, Zuluaga P, Muga R, et al. Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action. Addict Sci Clin Pract, 2024,19(1):19.
[20] Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2020,71(1):306-333.
[21] Fuster D, Samet JH. Alcohol use in patients with chronic liver disease. N Engl J Med, 2018,379(13):1251-1261.
[22] Vannier AGL, Shay JES, Fomin V, et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw Open, 2022,5(5):e2213014.
[23] Vannier AGL, Przybyszewski EM, Shay J, et al. Psychotherapy for alcohol use disorder is associated with reduced fisk of incident alcohol-associated liver disease. Clin Gastroenterol Hepatol, 2023,21(6):1571-1580,e7.
[24] Shah ND, Ventura-Cots M, Abraldes JG, et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol, 2019,17(11):2320-2329,e12.
[25] He Y, Hwang S, Ahmed YA, et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol, 2021,18(1):18-37.
[26] Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol, 2019,70(2):273-283.
[27] Nilsson E, Anderson H, Sargenti K, et al. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther, 2019 ,49(11):1421-1430.

Management of patients with alcohol consumption disorder

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Su Ya, Wang Bingyuan. Alcoholic liver disease is not metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 5-8.
[2]	Zhao Caixia, Yang Song. Fecal microbiota transplantation in treatment of patients with severe alcoholic hepatitis [J]. Journal of Practical Hepatology, 2025, 28(1): 9-12.
[3]	Huang Jiawei, Ji Yali, Zhou Ling, et al. SAF score and fatty liver inhibition of progression algorithm in evaluation of liver fibrosis in patients with metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 48-51.
[4]	Guo Zhen, Wang Xin, Niu Panxia. Factors influencing the occurrence of hepatitis B viral reactivation and drug-induced liver injury during anti-tuberculosis treatment in patients with serum HBsAg-positive pulmonary tuberculosis [J]. Journal of Practical Hepatology, 2025, 28(1): 68-71.
[5]	Yang Shuang, Gao Xuesong, Duan Xuefei. Refractory primary biliary cholangitis:current landscape and perspective [J]. Journal of Practical Hepatology, 2025, 28(1): 156-159.
[6]	He Zhenwen, Xu Gang, Meng Hua, et al. Tenofovir amibufenamide in re-treatment of patients with chronic hepatitis B and low-level viremia [J]. Journal of Practical Hepatology, 2024, 27(6): 828-831.
[7]	Chen Rongrong, Jiang Lili, Cao Lihua. Serum IL-6, IL-8 and IL-10 levels and their impact on response to steroid therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2024, 27(6): 852-855.
[8]	Wei Xinhuan, Liu Yali, Zhang Jing, et al. Current landscape and future perspectives of metabolic-associated fatty liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 641-645.
[9]	Jia Shuangzhen, Wu Tianwei, Wu Jie. MicroRNA-122 in non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2024, 27(5): 646-649.
[10]	Zhang Zhiqiang, Fang Jian, Li Dongliang. Strategy and challenges of interventional treatment in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2024, 27(5): 650-653.
[11]	Ran Shurong, Liu Yang, Lei Lan. Risk factors of low-level viremia and rescue switch treatment to tenofovir alafenamide fumarate in entecavir-treated patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(5): 681-684.
[12]	Chen Sitong, Wei Xiaodie, Wei Xinhuan, et al. Diagnosis and treatment of patients with metabolic dysfunction-associated steatotic liver disease [J]. Journal of Practical Hepatology, 2024, 27(4): 481-483.
[13]	Liu Yali, Zhang Jing. Child and adolescent metabolic dysfunction-associated fatty liver disease:current state of the art and perspectives [J]. Journal of Practical Hepatology, 2024, 27(4): 488-491.
[14]	Xue Lina, Zhu Guobing, Wu Linlin, et al. Virological response to tenofovir alafenamide in patients with low-level viremia chronic hepatitis B after entecavir treatment [J]. Journal of Practical Hepatology, 2024, 27(4): 519-522.
[15]	Zhao Weibo, Wang Yuan, Kong Lingjia, et al. Effect of balloon-compression endoscopic injection sclerotherapy in the treatment of patients with decompensated stage of hepatitis B cirrhosis and esophageal varices [J]. Journal of Practical Hepatology, 2024, 27(4): 559-562.